Home › Compare › PSCBF vs STAG

PSCBF vs STAG: Dividend Comparison 2026

PSCBF yields 1818.18% · STAG yields 3.44%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PSCBF wins by $4103414683.82M in total portfolio value
10 years
PSCBF
PSCBF
● Live price
1818.18%
Share price
$0.11
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4103414683.84M
Annual income
$3,702,796,788,756,407.00
Full PSCBF calculator →
STAG
STAG Industrial Inc.
● Live price
3.44%
Share price
$36.09
Annual div
$1.24
5Y div CAGR
0.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$18.3K
Annual income
$462.22
Full STAG calculator →

Portfolio growth — PSCBF vs STAG

📍 PSCBF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPSCBFSTAG
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PSCBF + STAG cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
PSCBF pays
STAG pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PSCBF
Annual income on $10K today (after 15% tax)
$154,545.45/yr
After 10yr DRIP, annual income (after tax)
$3,147,377,270,442,946.00/yr
STAG
Annual income on $10K today (after 15% tax)
$292.45/yr
After 10yr DRIP, annual income (after tax)
$392.89/yr
At 15% tax rate, PSCBF beats the other by $3,147,377,270,442,553.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PSCBF + STAG for your $10,000?

PSCBF: 50%STAG: 50%
100% STAG50/50100% PSCBF
Portfolio after 10yr
$2051707341.93M
Annual income
$1,851,398,394,378,434.50/yr
Blended yield
90.24%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on STAG right now

PSCBF
No analyst data
Altman Z
-5.7
Piotroski
4/9
STAG
Analyst Ratings
9
Buy
9
Hold
3
Sell
Consensus: Buy
Price Target
$45.00
+24.7% upside vs current
Range: $39.00 — $59.00
Altman Z
1.2
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PSCBF buys
0
STAG buys
0
No recent congressional trades found for PSCBF or STAG in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPSCBFSTAG
Forward yield1818.18% ✓3.44%
Annual dividend / share$2.00 ✓$1.24
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0.3% ✓
Portfolio after 10y$4103414683.84M ✓$18.3K
Annual income after 10y$3,702,796,788,756,407.00 ✓$462.22
Total dividends collected$4074760433.31M ✓$4.0K
Payment frequencyquarterlymonthly
SectorStockREIT

Year-by-year: PSCBF vs STAG ($10,000, DRIP)

YearPSCBF PortfolioPSCBF Income/yrSTAG PortfolioSTAG Income/yrGap
1← crossover$192,518$181,818.18$10,665$345.09+$181.9K → PSCBF
2$3,477,331$3,271,336.99$11,364$357.70+$3.47M → PSCBF
3$58,943,217$55,222,471.89$12,098$370.43+$58.93M → PSCBF
4$937,891,469$874,822,227.57$12,869$383.28+$937.88M → PSCBF
5$14,012,869,532$13,009,325,660.38$13,677$396.23+$14012.86M → PSCBF
6$196,647,994,247$181,654,223,846.76$14,524$409.27+$196647.98M → PSCBF
7$2,592,865,386,485$2,382,452,032,641.56$15,411$422.41+$2592865.37M → PSCBF
8$32,132,661,421,271$29,358,295,457,731.54$16,339$435.61+$32132661.40M → PSCBF
9$374,409,247,740,494$340,027,300,019,734.44$17,311$448.89+$374409247.72M → PSCBF
10$4,103,414,683,838,736$3,702,796,788,756,407.00$18,327$462.22+$4103414683.82M → PSCBF

PSCBF vs STAG: Complete Analysis 2026

PSCBF — Stock

Pascal Biosciences Inc., a biotechnology company, engages in the research and development of products for the treatment of cancer, and for the improvement of the immune system. The company's development portfolio includes PAS-403, a mitosis inhibitor that blocks cell division for the treatment of glioblastoma and brain metastases originating from other cancers; and PAS-393, an immune-stimulatory cannabinoid designed to restore the immunogenicity of tumor cells with checkpoint inhibitor therapy for use in cancer treatment. It is also developing a B-cell targeted antibody for acute lymphoblastic leukemia and B cell lymphomas; and cannabinoid therapeutic products for the treatment of COVID-19. The company has an exclusive license agreement with the University of Washington to develop a cannabinoid-based product for the treatment of glioblastoma multiforme and brain metastases; and a collaborative research agreement with SoRSE Technology Corporation to advance PAS-393 into clinical testing. Pascal Biosciences Inc. was incorporated in 2011 and is headquartered in Seattle, Washington.

Full PSCBF Calculator →

STAG — REIT

STAG Industrial, Inc. (NYSE: STAG) is a real estate investment trust focused on the acquisition and operation of single-tenant, industrial properties throughout the United States. By targeting this type of property, STAG has developed an investment strategy that helps investors find a powerful balance of income plus growth.

Full STAG Calculator →
📬

Get this PSCBF vs STAG comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PSCBF vs SCHDPSCBF vs JEPIPSCBF vs OPSCBF vs KOPSCBF vs MAINPSCBF vs PLDPSCBF vs EQRPSCBF vs VICI

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.